View
215
Download
0
Category
Preview:
Citation preview
EICOSANOIDE - ihre Beteiligung an physiologischen und pathophysiologischen Prozessen �
TC Info+Veröffentlichungen-06-2005.doc 1
www.talkingcells.org
Allgemeine Informationen TalkingCells befasst sich mit der in vitro Untersuchung weißer Blutzellen, welche die Information über Erkrankungen und sogar deren Vorstufen 'erzählen', d.h. erkennen lassen.
Veränderte Stoffwechselvorgänge können Wegbereiter aber auch Ursache verschiedener Erkrankungen sein. Der Nachweis der hierbei von den Zellen gebildeten Stoffwechselprodukte (Mediatoren) ermöglicht die Erkennung pathologischen Prozesse und den Rückschluss auf mögliche pathobiochemische Mechanismen. Eicosanoide erwiesen sich hierbei als bedeutsame Informationsträger hinsichtlich normaler und veränderter Stoffwechselprozesse. Kürzlich wurden Funktionelle Eicosanoid Teste (z.B. LiPiDoC-AIT) für den klinischen Alltag entwickelt.
Einsatzgebiete Erkrankungen der oberen und unteren Atemwege
(z. B. Fließschnupfen, Nasennebenhöhlenentzündungen, Nasenpolypen, Asthma).
Hauterkrankungen (z.B. Nesselsucht
Veränderungen im Magen-Darm-Kanal (z.B. Magengeschwüre, entzündliche Darmerkrankungen)
sowie eine Reihe weiterer Erkrankungen
Praktischer Nutzen Der Funktionelle-Eicosanoid-Test
erleichtert und sichert die Diagnose bietet Therapiealternativen hat Bedeutung für die OP-Planung erkennt Neigungen zu Krankheiten bereits im Vorfeld, noch bevor
Beschwerden auftreten und die üblichen Untersuchungsmöglichkeiten fündig werden.
ist risiko-freie für den Patienten, ist einfach und zeitsparend (ambulante Blutabnahme) durchzuführen ist kostengünstig: - vermeidet zusätzliche Krankenhausaufenthalte - durch vorbeugende Maßnahmen lassen sich
Erkrankungen herauszögern oder sogar verhindern
unterstützt das Aufklärungsgespräch mit dem Patienten
EICOSANOIDE - ihre Beteiligung an physiologischen und pathophysiologischen Prozessen �
TC Info+Veröffentlichungen-06-2005.doc 2
www.talkingcells.org
Analgetika-Intoleranz: Das verkannte Krankheitsbild
Nur bei einem Teil der Patienten gibt sich die Analgetika-Intoleranz ohne spezielle Diagnostik zu erkennen: wenn stets nach Verabreichung von Analgetika die zuvor beschriebenen Erscheinungen auftreten - hier kann auf den Test verzichtet werden. Wo aber ein solcher Zusammenhang verborgen bleibt, hilft der Test bei der Aufklärung.
Dies ist der Fall, wenn die Beschwerden und Veränderungen erst mit großer Verzögerung eintreten, z.B. bei Nasenpolypen. Aber auch andere Stoffe können für die Symptome verantwortlich sein, z.B. Nahrungsmitteln oder Körperpflegeprodukte und Kosmetika.
Wurden bislang solche Zusammenhänge nicht erkannt, ist dies heute mit LiPiDoC-AIT möglich; galten die Betroffenen als chronisch progredient krank, so sind sie heute einer Prophylaxe und Therapie zugängig.
Erscheinungsformen der Analgetika-Intoleranz
Intoleranzen gegenüber schmerzlindernden oder schmerzstillenden Arzneimitteln (Analgetika) zählen nicht zu den Volkskrankheiten, obgleich sie weitverbreitete Erkrankungen und Beschwerden (z.B. Urtikaria, Polyposis nasi, Asthma bronchiale, Magen-Darm-Beschwerden) auslösen, die mit lebensbedrohlichen Reaktionen des Körpers einhergehen können. Wie bei vielen anderen Erkrankungen mit ähnlichem Hintergrund ist bei der Analgetika-Intoleranz von einer gewissen Veranlagung auszugehen, die zudem von äußeren Faktoren verstärkt werden kann. Die Analgetika-Intoleranz geht einher mit einer veränderten Zellstoffwechsels ungesättigter Fettsäuren. Durch verschiedene, derzeit nicht bekannte Einflüsse zeigen sich typische Beschwerden meist im Erwachsenenalter. Nicht selten gibt es bereits im Kindesalter Hinweise auf Erkrankungen, etwa als Nasenschleimhautentzündung ohne Infekt und Allergie. Analgetika kommen in den erwähnten Schmerzmitteln vor, aber auch in verschiedenen Produkten, die Salicylsäure-Derivate enthalten, wie z.B. in getrockneten Früchten, Gewürzen oder als Konservierungsmittel in Körperpflegeprodukten oder Stoffen.
EICOSANOIDE - ihre Beteiligung an physiologischen und pathophysiologischen Prozessen �
TC Info+Veröffentlichungen-06-2005.doc 3
www.talkingcells.org
Diagnostik der Analgetika-Intoleranz
Eine aussagefähige Diagnose einer Analgetika-Intoleranz kann somit von weitreichender Bedeutung für die Gesundheit Ihres Patienten sein. Neben der Anamnese stand bisher nur der Provokationstest zur Verfügung. Dessen Durchführung ist sehr zeitaufwändig, bedarf erheblicher apparativer Voraussetzungen und sollte nur von ausgewiesenen Spezialisten vorgenommen werden. Zudem ist er mit erheblichen Risiken für Ihren Patienten verbunden. Darüber hinaus erkennt der Provokationstest vorzugsweise Atemwegs-bedingte Analgetika-Intoleranzen. Mit üblichen Laboruntersuchungen ist die Analgetika-Intoleranz nicht erkennbar. Das TalkingCells-Untersuchungsprinzip mit dem LiPiDoC-AIT ist hier eine sinnvolle Alternative für eine Anagetika-Intoleranz-Typisierung (AIT). Dessen Vorteile sind:
risikofrei, da in vitro (d.h. im Reagenzglas)
ambulant, d.h. kein stationärer Krankenhausaufenthalt
ersetzt i.d.R. Provokation mit Analgetika
erkennt frühzeitig Neigung zu Erkrankungen, die durch Analgetika-Intoleranz bedingt sein
können (Risikobewertung)
liefert ein objektives Ergebnis
gibt Hinweis auf Therapiealtenativen
misst den Therapieerfolg
Nachfolgend wurde eine kleine Auswahl von Veröffentlichungen zusammengestellt, in denen die Beteiligung von Eicosanoiden an pathologischen Prozessen zum Ausdruck kommt.
EICOSANOIDE - ihre Beteiligung an physiologischen und pathophysiologischen Prozessen �
TC Info+Veröffentlichungen-06-2005.doc 4
www.talkingcells.org
Inhaltsübersicht
Abstracts Eicosanoide und Atemwege 5 Eicosanoide und Haut 22 Eicosanoide und Magen-Darm-Kanal 23 Eicosanoide und Nervensystem 24 Eicosanoide und Zahnheilkunde 26 Eicosanoide und Tumortherapie 28 Eicosanoide und Regulation ihrer Synthese 30
Abstracts � Kurzübersicht 32-34
Publikation Dynamics of eicosanoids in peripheral blood cells during bronchial provocation in
aspirin-intolerant asthmatics. Schäfer D, Schmid M, Göde UC, Baenkler HW.
Eur Respir J. 1999 Mar; 13(3): 638-646.
EICOSANOIDE - ihre Beteiligung an physiologischen und pathophysiologischen Prozessen �
TC Info+Veröffentlichungen-06-2005.doc 5
www.talkingcells.org
ABSTRACTS
Eicosanoide und Atemwege
ASA-induced release of histamine from nasal mucous membranes
in analgesic intolerance and polyposis nasi.
1Hosemann WG, 2Baenkler HW, 2Gunther F.
Rhinology. 1990 Dec; 28(4): 231-238.
1Department of O.R.L., 2Medical Clinic III, Dept. of Allergology, University of Erlangen-Nürnberg, Fed. Rep. of Germany.
Tissue samples from the polypous mucous membrane and the inferior nasal
concha were taken from 13 patients with polyposis nasi and from 12 other
patients with an additional intolerance to analgesics. The tissue of the inferior
nasal concha from patients without polyposis nasi served as a control. The
relative histamine content of the samples (in ng/mg dry weight) and the relative
histamine release (in %) after addition of acetylsalicylic acid (ASA) were
determined.
A significantly higher relative histamine content in the tissue samples of polyp
patients without an intolerance to analgesics was seen in comparison to the other
two groups. The relative histamine release of both patient groups with nasal
polyposis was comparable. The control group exhibited both an increased
spontaneous release of histamine as well as a higher relative histamine release
from the tissue of the inferior nasal concha.
EICOSANOIDE - ihre Beteiligung an physiologischen und pathophysiologischen Prozessen �
TC Info+Veröffentlichungen-06-2005.doc 6
www.talkingcells.org
Eicosanoids from biopsy of normal and polypous nasal mucosa.
1Baenkler HW, 1Schäfer D, 2Hosemann W.
Rhinology. 1996 Sep; 34(3): 166-170.
1Medical Clinic III, Dept. of Allergology, 2Department of O.R.L., University of Erlangen-Nürnberg, Germany.
In order to clarify the influence of inflammatory mediators of the arachidonic acid
cascade in the mechanism of nasal polyp growth, peptido-leukotriene (pLT),
prostaglandin E2 (PGE2) and thromboxane B2 (TXB2) synthesis was
investigated. In addition to several stimuli, functionally intact human biopsy
specimens of polypous and normal tissue were incubated.
Especially remarkable was the significantly increased release of pLT by polypous
tissue upon arachidonic acid stimulation, in contrast to only slightly elevated
PGE2 release compared to normal tissue. Basic release of pLT and PGE2 was
similar for polypous and normal tissue. Examining TXB2 release, no significant
difference was observed with regard to the origin of tissues.
These data support an altered pattern of the lipoxygenase and cyclo-oxygenase
pathways when tissue becomes irritated and suggest their involvement in the
aetiopathogenesis of nasal polyps.
EICOSANOIDE - ihre Beteiligung an physiologischen und pathophysiologischen Prozessen �
TC Info+Veröffentlichungen-06-2005.doc 7
www.talkingcells.org
Dynamics of eicosanoids in peripheral blood cells during bronchial
provocation in aspirin-intolerant asthmatics.
1Schäfer D, 2Schmid M, 2Göde UC, 1Baenkler HW.
Eur Respir J. 1999 Mar; 13(3): 638-646.
2Medical Clinic III, Dept of Allergology, 2Dept. of O.R.L.University of Erlangen-Nürnberg, Germany.
The underlying mechanisms of bronchoconstriction in aspirin-intolerant
asthmatics (AIAs) are still unknown, but the hypothesis of an altered metabolism
of arachidonic acid is generally accepted. So far, no in vitro test for aspirin
intolerance is available. The hypothesis that the profile of eicosanoid mediators is
changed in AIA-even before aspirin challenge was tested.
The release of prostaglandin E2 (PGE2), peptidoleukotrienes and histamine was
measured using competitive enzyme immunoassays in 10 asthmatics with a
history of aspirin intolerance, 10 controls and eight aspirin-tolerant asthmatics
(ATAs) before and after bronchial provocation with lysine-aspirin.
Comparing basal release of eicosanoids before challenge, peptidoleukotrienes
were significantly elevated and PGE2 was vastly reduced in AIAs, whereas ATAs
had elevated basal peptidoleukotrienes but only slightly reduced basal PGE2. The
decrease in forced expiratory volume in one second (FEV1) was not associated
with changes in histamine release. After aspirin challenge, there was a massive
increase of already elevated peptidoleukotrienes in AIAs, but not in ATAs.
Arachidonic acid-induced PGE2 release in AIAs was not significantly changed,
whereas it was significantly reduced in ATAs and healthy controls. Histamine
release was unaffected by aspirin challenge in all three groups.
There is a typically altered profile of eicosanoids in aspirin-intolerant asthmatics
which could make in vitro diagnosis of aspirin intolerance possible.
EICOSANOIDE - ihre Beteiligung an physiologischen und pathophysiologischen Prozessen �
TC Info+Veröffentlichungen-06-2005.doc 8
www.talkingcells.org
Arachidonic acid metabolism in nasal tissue and peripheral blood
cells in aspirin intolerant asthmatics.
1Schmid M, 1Göde U, 2Schäfer D, 1Wigand ME.
Acta Otolaryngol. 1999 Mar; 119(2): 277-280.
1Dept. of Otorhinolaryngology, 2Medical Clinic III, Dept of Allergology, University of Erlangen-Nürnberg, Erlangen, Germany.
Aspirin intolerance (AI) is characterized by polypous rhinosinusitis, bronchial
asthma and adverse reactions to aspirin. The common intolerance to all
cyclooxygenase inhibitors allows us to focus study of the pathogenesis of AI on
the metabolism of arachidonic acid (AA).
We studied the metabolism of AA in nine aspirin intolerant asthmatics (AIA) and
eight healthy volunteers (controls) by measuring prostaglandin E2 (PGE2) and
peptido-leukotrienes (pLT = LTC4/D4/E4) in nasal tissue and peripheral blood
cells (PBCs) using a specific immunoassay.
In all patients with AI the tests were performed before and after bronchial
provocation with lysine-ASA. In the control group the tests were done before and
after 500 mg ASA p.o. The release of pLT in nasal polyps of AIA was found to be
significantly higher than in normal mucosa of AIAs and controls. In every tissue a
significant increase of pLT after aspirin challenge was observed. Nasal polyps of
AIA show a significantly lower release of PGE2 than normal mucosa of AIAs and
controls. Peripheral blood cells of AIA show a significantly higher release of pLT
and a significantly lower release of PGE2 than PBCs of controls.
Therefore clinical manifestations of AI may be based on an alteration of AA
metabolism in AIA.
EICOSANOIDE - ihre Beteiligung an physiologischen und pathophysiologischen Prozessen �
TC Info+Veröffentlichungen-06-2005.doc 9
www.talkingcells.org
[Significance of eosinophilic granulocytes in relation to allergy and
aspirin intolerance in patients with sinusitis polyposa]
[Article in German]
Kaldenbach T, Schäfer D, Gosepath J, Bittinger F, Klimek L, Mann WJ. Laryngorhinootologie. 1999 Aug; 78(8): 429-434.
Hals-, Nasen-, Ohrenklinik und Poliklinik der Johannes Gutenberg-Universitat Mainz.
BACKGROUND: The development of nasal polyps might be influenced by
different factors such as mucosal inflammation. Infiltration with eosinophils is a
common finding, although in largely different quantitis.
PATIENTS AND METHODS: We investigated 58 patients suffering from nasal
polyps who were assigned for endonasal sinus surgery based on endoscopic and
CT findings. Out of these patients, 52% have already had sinus surgery and had
recurrent polyps. All patients were subjected to both, allergy testing and a
functional in vitro test for aspirin intolerance. During surgery, tissue samples
were gained and send for histological examination with special respect to
eosinophil infiltration.
RESULTS: Eosinophil infiltration was observed in 66% of all patients. 37
patients (64%) exhibited aspirin intolerance only, four (7%) had a positive
allergy test only, in 9 patients (15%) both, allergy and aspirin intolerance were
diagnosed. Allergy and aspirin intolerance were accompanied by eosinophil tissue
infiltration. Eosinophil infiltration was more common and more severe if allergy
and aspirin intolerance were found together compared with the tissue
eosinophilia in patients with either one entity.
CONCLUSION: This study confirms the importance of eosinophil infiltration in
the pathogenesis of severe or recurrent nasal polyps based on allergy and aspirin
intolerance. A coincidance of allergy and aspirin intolerance was found in an
unexpected high number of patients.
EICOSANOIDE - ihre Beteiligung an physiologischen und pathophysiologischen Prozessen �
TC Info+Veröffentlichungen-06-2005.doc 10
www.talkingcells.org
Aspirin intolerance in patients with chronic sinusitis.
1Gosepath J, 1Hoffmann F, 1Schäfer D, 2Amedee RG, 1Mann WJ.
ORL J Otorhinolaryngol Relat Spec. 1999 May-Jun; 61(3): 146-150.
1Department of Otolaryngology, University of Mainz, School of Medicine, Mainz, Germany; 2Tulane University Medical Center, New Orleans, School of Medicine, New Orleans, La., USA Department of Otolaryngology
Aspirin intolerance in patients with chronic sinusitis is often a cause of early
recurrence of symptoms after surgical treatment.
This study assesses 84 patients who were tested for acetylsalicylic acid
intolerance after presenting with symptoms like chronic rhinosinusitis, sometimes
bronchial asthma, coexisting allergies or a history of aspirin sensitivity.
Nasal polyposis was found in a majority of cases, often recurrent after previous
surgery. The levels of eicosanoids such as peptido-leukotrienes and prostaglandin
E2 were analyzed in isolated blood cells and compared with a healthy control
group. Aspirin-intolerant patients showed elevated basal levels of peptido-
leukotrienes and reduced basal levels of prostaglandin E2. Test results were
graded in a system ranging from positive (68%), signifying aspirin intolerance, to
borderline (18%) and negative results (14%).
After screening patients with clinical findings indicating a possible aspirin
intolerance, the results of this investigation reveal a strong correlation between
the clinical symptomatology and the in vitro parameters of eicosanoid levels in
isolated blood cells, indicating the need to induce aspirin tolerance to reduce the
risk of recurrent rhinosinusitis.
EICOSANOIDE - ihre Beteiligung an physiologischen und pathophysiologischen Prozessen �
TC Info+Veröffentlichungen-06-2005.doc 11
www.talkingcells.org
Prostaglandin E2 activates the ciliary beat frequency of cultured
human nasal mucosa via the second messenger cyclic adenosine
monophosphate.
Haxel BR, Schäfer D, Klimek L, Mann WJ.
Eur Arch Otorhinolaryngol. 2001; 258: 230-235.
Department of Otorhinolaryngology Johannes-Gutenberg University Mainz, Germany.
Prostaglandins influence the ciliary beat frequency (CBF) of ciliated nasal
epithelial cells and a stimulatory effect has been described for prostaglandin E2
(PGE2). Until now, it is not known whether PGE2 has direct ciliostimulatory
properties or acts through a second messenger.
In this study we investigated whether cyclic adenosine monophosphate (cAMP) is
implicated in the signal transduction pathway of PGE2-induced activation of CBF.
Ciliated cells of the nasal mucosa were cultured for up to 5 days whereafter the
culture medium was removed and the cells were incubated with different
concentrations of test solutions.
The ciliated cells were recorded under a phase-contrast microscope and viewed
in slow motion to count the frequency. PGE2 led to a dose-dependent increase in
CBF. This became significant at concentrations of 10(-10) and 10(-5) M (P <
0.01) but not at 10(-13) M (P > 0.05). Addition of cAMP (10(-10) to 10(-5) M)
caused a significant (P < 0.01) increase in CBF, whereas depletion of
endogenous cAMP after pre-incubation with the adenylate cyclase activator
forskolin (10(-5) M) prevented the PGE2-induced increase in CBF (P > 0.05). The
ciliostimulatory effect of PGE2 depends on an intact functioning of adenylate
cyclase.
These results point out that cAMP is directly implicated in the signal transduction
pathway of PGE2-induced stimulation of CBF in cultured human ciliated cells of
the nasal mucosa.
EICOSANOIDE - ihre Beteiligung an physiologischen und pathophysiologischen Prozessen �
TC Info+Veröffentlichungen-06-2005.doc 12
www.talkingcells.org
Individual monitoring of aspirin desensitization.
Gosepath J, Schaefer D, Amedee RG, Mann WJ.
Arch Otolaryngol Head Neck Surg. 2001 Mar; 127(3): 316-321.
Department of Otolaryngology-Head and Neck Surgery, Mainz Medical School, Langenbeckstrasse 1, 55101 Mainz, Germany.
BACKGROUND: Patients with aspirin-sensitive rhinosinusitis, which is frequently associated with intrinsic bronchial asthma, can be desensitized by long-term treatment with oral aspirin. The exact mechanisms of this desensitization remain obscure, but modulations of the eicosanoid pathway occur and can be monitored with the help of a practicable in vitro assay on mixed leukocyte cultures. OBJECTIVE: To monitor the effect of low-dose aspirin desensitization therapy, 100 mg/d, objectively by an in vitro assay. DESIGN: In a prospective study, 30 patients with aspirin intolerance, who were treated following a desensitization protocol with a dose of oral aspirin of only 100 mg/d were followed up for 1 year and reassessed every 3 months clinically and in vitro. RESULTS: Twenty-five patients showed a normalization of in vitro eicosanoid levels during this period, 4 showed some improvement, and 1 showed no therapeutic effect on eicosanoid release. Clinical follow-up revealed a low recurrence rate of nasal polyposis, with recurrent disease only in 4 individuals who also showed no normalization of eicosanoid release levels. Furthermore, a reduction of the average incidence of purulent episodes of sinusitis was seen after 1 year. Of 12 patients with asthma, 9 experienced marked improvement in pulmonary function. Of 16 individuals with a marked impairment of nasal breathing, 14 felt an increase of nasal patency, and 7 of 11 patients with pretreatment hyposmia had an improved sense of smell after 1 year. CONCLUSIONS: Desensitization therapy in patients with aspirin-sensitive rhinosinusitis can be successfully performed with low oral doses of aspirin, and the individual course throughout the desensitization can be monitored with the help of an in vitro analysis of eicosanoid release from mixed leukocyte cultures.
EICOSANOIDE - ihre Beteiligung an physiologischen und pathophysiologischen Prozessen �
TC Info+Veröffentlichungen-06-2005.doc 13
www.talkingcells.org
Analgetika-Intoleranz: Langzeitergebnisse bis zu 3 Jahren bei
adaptiver Desaktivierung mit einer täglichen Erhaltungsdosis von
100 mg Aspirin
Gosepath, D. Schäfer, W. J. Mann Laryngorhinootologie. 2002; 81: 732-738.
Universitäts-HNO-Klinik Mainz (Direktor: Prof. Dr. med. Dr. h. c. W. J. Mann)
Hintergrund: Obwohl die pathophysiologischen Grundlagen des Krankheitsbildes des Analgetika-Intoleranzsyndromes bis heute nicht vollständig erforscht sind, deuten eine Vielzahl von Untersuchungen auf eine Störung des Eicosanoidstoffwechsels als wesentlichen ursächlichen Faktor hin. Die Analyse der Eicosanoidfreisetzung in vitro ist in den letzten Jahren als hilfreiches Instrument in der Diagnostik dieses Krankheitsbildes etabliert worden. Diese ermöglicht zusätzlich eine objektive Therapiekontrolle während der adaptiven Desaktivierungstherapie. Methodik: Im Rahmen der vorliegenden prospektiven Untersuchung wurden 30 Patienten, bei denen zwischen 1996 und 2000 an unserer Klinik eine Analgetika-Intoleranz diagnostiziert wurde, zwischen einem und drei Jahre lang einer adaptiven Desaktivierungstherapie unterzogen. Hierbei wurde eine Erhaltungsdosis von nur 100 mg Aspirin pro Tag verabreicht. Es erfolgte eine regelmäßige Kontrolle der klinischen wie auch der in vitro Parameter. Es traten bei dieser Dosierung keine durch Aspirin verursachten unerwünschten Nebenwirkungen auf. Ergebnisse: Es zeigte sich eine klare positive Korrelation zwischen klinischer Symptomatik und Veränderungen des Eicosanoidstoffwechsels. Gemessen an der Rezidivrate der Polyposis nasi, dem Schweregrad des intrinsischen Asthma bronchiale und dem Riechvermögen wurde die Therapie bei 25 Patienten langfristig als erfolgreich bewertet. Eine Unterbrechung oder ein Absetzen der Therapie führte zu einer erneuten klinischen Verschlechterung. Schlussfolgerungen: Die Ergebnisse dieser Untersuchung belegen die Wirksamkeit einer Desaktivierungstherapie bei Patienten mit Aspirinintoleranz mit einer nebenwirkungsfreien Dosierung von 100 mg. Der langfristige Erfolg einer solchen Therapie kann nur durch eine anhaltende, möglichst lebenslange Einnahme geringer Dosen von Aspirin gesichert werden.
EICOSANOIDE - ihre Beteiligung an physiologischen und pathophysiologischen Prozessen �
TC Info+Veröffentlichungen-06-2005.doc 14
www.talkingcells.org
[Aspirin Sensitivity: Long Term Follow-up After Up to 3 Years of
Adaptive Desensitization Using a Maintenance Dose of 100 mg of
Aspirin a Day]
Gosepath, D. Schäfer, W. J. Mann
Laryngorhinootologie. 2002; 81: 732-738.
Background: The full clinical picture of aspirin intolerance, Sampter's triad, is
associated with nasal polyposis, clinical sensitivity to most non steroidal
antiinflammatory drugs (NSAID) and intrinsic bronchial asthma. But the triad can
be incomplete and nasal polyposis can be the first clinical symptom of aspirin
sensitivity. Although the exact mechanisms of aspirin intolerance as well as those
of desensitization remain obscure, an in vitro assay on eicosanoid metabolism
has been proven to be helpful in diagnosis and treatment as it correlates well to
the individual severity of clinical symptoms.
Methods: For this investigation 30 patients, who were undergoing adaptive
desensitization for aspirin intolerance, were followed-up between 1 and 3 years.
They received a maintenance dose of oral aspirin of only 100 mg a day after an
initial application of higher doses. Their clinical course as well as their in vitro
parameters of eicosanoid release were monitored throughout the individual
observation period.
Results: Desensitization was successful in 25 of the 30 patients regarding the
recurrence rate of nasal polyps, severity of bronchial asthma and sense of smell.
There was a clear positive correlation between clinical and in vitro parameters.
Discontinuing of aspirin therapy lead to worsening of clinical symptoms,
regardless of the prior duration of treatment.
Conclusions: This article reviews the role of the in vitro assay and presents a
desensitization protocol that can be maintained as a long term treatment without
adverse side effects. Results suggest that the recurrence rate of nasal polyps
after surgical therapy can be reduced using this protocol, however, only long
term treatment can secure a beneficial outcome over time.
EICOSANOIDE - ihre Beteiligung an physiologischen und pathophysiologischen Prozessen �
TC Info+Veröffentlichungen-06-2005.doc 15
www.talkingcells.org
Diagnostik des Analgetika-Intoleranz-Syndroms mittels
funktioneller Zelltestung (Analgetika-Intoleranz-Test: AIT)
1Hecksteden K, D. 1Schäfer D, B.A. 1Stuck1, 1,2Klimek L, 1Hörmann K.
Allergologie. 2003 Jul; 26(7): 263-271.
1HNO-Klinik, Universitätsklinikum Mannheim, 2Zentrum für Rhinologie und Allergologie, Wiesbaden
Das klinisch manifeste Analgetika-Intoleranz-Syndrom (AIS) ist typischerweise
durch rezidivierende Polyposis nasi, Asthma bronchiale und Analgetika-
Unverträglichkeit gekennzeichnet. Es beruht nach gängiger Meinung auf
Dysbalancen im Arachidonsäure-Metabolismus, ausgelöst durch die Einnahme
von non-steroidalen Antirheumatika (NSAR). Bisher sind in der Diagnostik des
AIS Anamnese und Provokationstests etabliert. Die Methoden der nasalen,
bronchialen und oralen Provokationstests sind für die Praxis umfangreich und für
die Patienten meist unangenehm und risikobehaftet. Ziel dieser Arbeit war es
herauszufinden, inwieweit ein komplikationsloses In-vitro-Verfahren mit
funktioneller Zelltestung (Analgetika-Intoleranz-Test: AIT) zur Diagnosesicherung
herangezogen werden kann.
Hierfür wurde die herkömmliche Diagnostik mit den Ergebnissen des AIT an 50
Patienten mit Verdacht auf Analgetikaintoleranz verglichen. Zur Kontrolle dienten
Tests an 38 Patienten mit leerer Anamnese und ohne klinische Zeichen einer
Polyposis oder eines Asthma bronchiale. Für die Sensitivität des Tests wurden
100%, für die Spezifität 73,3% berechnet, der negative Vorhersagewert des AIT
lag bei 100% und der positive Vorhersagewert bei 71%. Dies erklärt sich durch
eine Gruppe von Patienten, bei denen die herkömmliche Diagnostik zu einem
negativen, der AIT hingegen zu einem positiven Ergebnis gekommen war.
Eine Follow-up-Studie muß klären, ob bei diesen Patienten ein klinisch nicht
manifestes AIS vorliegt, oder ob der Test falsch-positive Ergebnisse liefert.
Zusammenfassend ist der AIT bisher � trotz der guten Ergebnisse � nicht zur
Diagnosesicherung eines AIS ausreichend, betrachtet man aber seine Vorteile in
Praktikabilität und Risikominimierung, so ist eine weitere Validierung des Tests
zu fordern.
EICOSANOIDE - ihre Beteiligung an physiologischen und pathophysiologischen Prozessen �
TC Info+Veröffentlichungen-06-2005.doc 16
www.talkingcells.org
Untreated chronic rhinosinusitis: a comparison of symptoms and
mediator profiles.
Kuehnemund M, Ismail C, Brieger J, Schaefer D, Mann WJ.
Laryngoscope. 2004 Mar; 114(3): 561-565.
Department of Otorhinolaryngology-Head and Neck Surgery, Mainz Medical School, Mainz, Germany.
OBJECTIVES/HYPOTHESIS: Since the early 1990s, the knowledge of inflammatory mediators involved in chronic rhinosinusitis has increased extensively. However, until the present no data on trends in mediator levels in the natural course of the exacerbation-free interval of chronic rhinosinusitis have been published. The purpose of the study was to examine how levels of inflammatory mediators and clinical findings in chronic rhinosinusitis relate over time in the absence of acute exacerbation. STUDY DESIGN: Prospective study. METHODS: The authors investigated 12 untreated patients with chronic rhinosinusitis and repeated clinical examinations and measurements of inflammatory mediators in the nasal mucosa (messenger RNA [mRNA]of interleukin-1beta; interleukins 3, 5, 6, and 8 [IL-3, IL-5, IL-6, and IL-8]; interferon gamma; tumor necrosis factor-alpha [TNF-alpha]; monocyte chemotactic proteins 1, 3, and 4 [MCP-1, MCP-3, and MCP-4]; and granulocyte-macrophage colony-stimulating factor [GM-CSF]), as well as measurements of peptido-leukotriene [PLT] and prostaglandin E2 [PGE2]) in nasal secretion over a period of 4 weeks. RESULTS: Clinically speaking, the symptom score significantly improved over the period of 4 weeks, whereas other clinical parameters (computed tomography score, endoscopy score, rhinomanometric values, saccharine transport time, ciliary beat frequency, and olfaction) varied insignificantly. Regarding proinflammatory and inflammatory mediators, only mRNA of IL-1beta, IL-6, IL-8, MCP-1, and TNF-alpha were detected in relevant amounts in nasal mucosa, and their levels decreased only insignificantly over the 4-week period. In nasal secretion, a slight decrease of PGE2 and PLT levels was observed over the same time period. CONCLUSION: Subjective symptoms may show a spontaneous improvement of approximately 25% in patients with so-called "stable" chronic rhinosinusitis over a 4-week period, whereas objective clinical parameters vary insignificantly. Messenger RNA of IL-1beta, IL-6, IL-8, MCP-1, and TNF-alpha, as well as PLT and PGE2 levels, are detectable and appear to play a role in the persistence of inflammation in chronic rhinosinusitis. Their levels decrease only insignificantly over time, even in the absence of acute exacerbation of disease, possibly rendering the mucosa more prone to recurrent acute episodes.
EICOSANOIDE - ihre Beteiligung an physiologischen und pathophysiologischen Prozessen �
TC Info+Veröffentlichungen-06-2005.doc 17
www.talkingcells.org
Experimentally induced nasal irritation.
1Mohammadian P, 2Schaefer D, 1Hummel T, 1Kobal G.
Rhinology. 1999 Dec; 37(4): 175-178.
1Dept. of Experimental and Clinical Pharmacology and Toxicology, 2Medical Clinic III, Dept. of Allergology, University of Erlangen-Nürnberg, Germany.
The aim of this study was to develop a method that is suited for the induction of
nasal irritation. For this purpose inflammatory responses were analysed after
challenging the nasal mucosa with experimentally induced cold, dry air (8 l/min,
22 degrees C, 20 %RH). To assess inflammatory effects we determined
inflammatory mediators (prostaglandin E2 [PGE2], thromboxane B2 TXB2[,
peptide leukotrienes, pLT [LTC4, LTD4, LTE4]) in nasal lavage fluid which was
sampled before, immediately after suprathreshold stimulation, and one hour
after termination of the stimulation. In addition, subjects estimated the intensity
of pain during the stimulation.
Cold, dry air produced strong painful sensations which increased throughout the
stimulation period. A significant increase of the inflammatory mediator pLT was
observed after stimulation; mean concentrations of PGE2 and TXB2 also showed
a tendency to increase. One hour after termination of the stimulation the
concentration of these inflammatory mediators returned to baseline which
indicates the reversibility of the effects of nasal irritation.
These data suggest, that this model may be a useful tool in investigations of
mucosal irritation as, for example, induced by environmental agents.
EICOSANOIDE - ihre Beteiligung an physiologischen und pathophysiologischen Prozessen �
TC Info+Veröffentlichungen-06-2005.doc 18
www.talkingcells.org
Leukotrienrezeptorantagonisten zur Rezidivprophylaxe bei der
ASS-assoziierten Polyposis - Erste klinische Ergebnisse zur
Wirkung auf entzündliche Gewebeprozesse
T. Grundmann, M. Töpfner
Laryngorhinootologie 2001; 80: 576-582.
Universitäts-Hals-Nasen-Ohrenklinik Hamburg-Eppendorf (Direktor: Prof. Dr. U. Koch)
Hintergrund: Die mit einer Aspirinintoleranz (AI) assoziierte Polyposis nasi et sinuum stellt aufgrund häufiger Rezidive ein besonderes therapeutisches Problem dar. Basierend auf neueren Untersuchungen, die ätiologisch Störungen im Arachidonsäuremetabolismus mit erhöhten Leukotrienspiegeln nachweisen konnten, wurden kausal in diesen Pathomechanismus eingreifende Therapeutika wie z. B. die Leukotrienrezeptorantagonisten (LTA) entwickelt. In der Behandlung des ASS-assoziierten Asthma bronchiale konnten erste klinische Erfolge in Bezug auf die pulmonale Symptomatik nachgewiesen werden, Untersuchungen zur Wirksamkeit auf die ASS-assoziierte Polyposis nasi et sinuum (ASSAP) liegen jedoch noch nicht vor. Ziel unserer Untersuchung war es daher, Leukotrienrezeptorantagonisten auf ihre therapeutische Wirksamkeit in Hinblick auf die entzündlichen Veränderungen der ASS-assoziierten Polyposis zu untersuchen. Methode: Hierzu wurden 18 Patienten unseres rhinologischen Klientels mit nachgewiesener AI und zusätzlich bestehenden pulmonalen Beschwerden, bei denen aufgrund einer Rezidivpolyposis eine operative Nasennebenhöhlensanierung indiziert war, postoperativ über ein Jahr mit dem LTA Montelukast therapiert. Als klinische Verlaufsparameter dienten subjektive Befundskalierungen, endoskopische Befundschemata und serologische Befunde (ECP). Zur zusätzlichen Beurteilung möglicher antiinflammatorischer Gewebeeffekte wurden immunhistologisch EG1/EG2-positive Zellen und die Interleukin 5-Spiegel im Gewebe der unteren Nasenmuscheln bestimmt. Ergebnisse: Bei den klinischen Untersuchungen war über einen Beobachtungszeitraum von zwölf Monaten unter LTA-Therapie endoskopisch keine Rezidivpolyposis nachweisbar, symptomatisch beschrieben die Patienten postoperativ einen dauerhaften Rückgang der rhinitischen und pulmonalen Beschwerden im Vergleich zur Kontrollgruppe die nur mit topischen Steroiden behandelt wurde. Ein reduzierter Anteil EG2-positiver Zellen sowie erniedrigte Interleukin 5-Spiegel lassen einen antiinflammatorischen Effekt der LTA bei der ASSAP vermuten. Schlussfolgerungen: Leukotrienantagonisten können bei Patienten mit ASS-assoziierter Polyposis eine therapeutische Alternative zur ASS-Toleranzinduktion zur postoperativen Rezidivprophylaxe darstellen.
EICOSANOIDE - ihre Beteiligung an physiologischen und pathophysiologischen Prozessen �
TC Info+Veröffentlichungen-06-2005.doc 19
www.talkingcells.org
[Treatment of ASS-Associated Polyposis (ASSAP) with a Cysteinyl
Leukotriene Receptor Antagonist - A Prospective Drug Study on its
Antiinflammatory Effects]
T. Grundmann, M. Töpfner
Laryngorhinootologie 2001; 80: 576-582.
Background: In a high rate of cases with recurrent polyposis an association with ASS-intolerance is detectable despite missing pulmonary symptoms. New examinations of a disturbed arachidonic acid metabolism lead to the development of new therapeutical options. Treatment with leukotriene-receptor antogonists (LTA) showed primarily good results in therapy of ASS-associated asthma. Methods: 18 patients with ASS-intolerance trias - diagnosed by oral provocation - were treated with the LTA Montelukast, after undergoing sinus surgery. Patients underwent a diagnostic pathway of provocation including four groups: recurrent chronic sinusitis, excessive polyposis, polyposis associated with asthma and anaphylactic symptoms after oral ASS-intake. Clinically we examined the following parameters periodically after sinus surgery: nasal and pulmonal symptoms by scoring levels, recurrency of polypoid hyperplasia by endoscopic follow-ups and serum ECP-levels. To evaluate antiinflammatory tissue effects of LTA EG1/EG2 labelled cells and cytokine levels of Interleukin 5 in mucosa samples of the lower turbinate were analysed under LTA-therapy. Results: Under therapy with LTA we saw a beneficial effect on nasal and pulmonary symptoms and a significant reduction of recurrent polyposis in endoscopic examinations in relation to the untreated group. Results were proven by a permanent reduction of serum ECP-level. A reduction of the rate of EG2-positive cells according to decreased Interleukin 5 levels in the nasal mucosa unter LTA-treatment assumed antiinflammatory effects on ASS-associated polyposis. Conclusions: We could demonstrate antiinflammatory effects of Leukotriene-Receptor-Antagonists primarily during postoperative treatment of patients with ASS-associated nasal polyps.
EICOSANOIDE - ihre Beteiligung an physiologischen und pathophysiologischen Prozessen �
TC Info+Veröffentlichungen-06-2005.doc 20
www.talkingcells.org
Analgetikasensitive Atemwegserkrankung: Diagnostik,
Risikoanalyse und Therapieplanung mittels FET
G Eger, D Schäfer, HW Baenkler Pneumologie 2004; 58 DOI: 10.1055/s-2004-819570 Medizinische Klinik III, Abteilung Allergologie, Universität Erlangen-Nürnberg,
Die Intoleranz gegenüber Salizylatanaloga kann sich mit chronisch entzündlicher
Reaktion an Haut, Atmungs- und Verdauungsorganen manifestieren und als
akutes Analgetikaasthma oder anaphylaktoide Akutreaktion in Erscheinung
treten. Als nahezu ubiquitäre Nahrungsmittelinhaltsstoffe sind Salizylate jedoch
nicht zu vermeiden. Zusätzliche Bedeutung erhält diese Intoleranzreaktion durch
die Tatsache, dass zu den wirksamen Analoga eine Vielzahl von Schmerzmitteln
und Entzündungshemmern aus der Gruppe der NSAID zählen.
Als Sonderform des NSAID-sensitiven Komplexes ist die Samter-Trias mit der
Kombination von Analgetikaintoleranz, Asthma und nasaler Polyposis bekannt.
Entzündungsaktivität und Akutreaktivität lassen sich in diesem Fall durch
Dauermedikation mit Aspirin verbessern (ASS-Desaktivierungstherapie).
Zur Sicherung der Salizylat- bzw. Analgetikaintoleranz ist bislang eine
risikoreiche ASS-Expositionstestung nicht zu umgehen, insbesondere wenn eine
langjährige Desaktivierungsbehandlung ansteht.
Auf Basis der Pathogenese in einem veränderten Arachidonsäuremetabolismus
wurde ein funktioneller Eicosanoidtest (FET) entwickelt, der die biochemisch
relevanten Vorgänge bei Salizylattoleranz und -intoleranz in vitro abbildet,
unabhängig von der jeweiligen Manifestationsform der Erkrankung. Die
biochemischen Daten des FET wurden mit den Ergebnissen von ASS-
Expositionstestungen und mit Therapieverläufen korreliert.
EICOSANOIDE - ihre Beteiligung an physiologischen und pathophysiologischen Prozessen �
TC Info+Veröffentlichungen-06-2005.doc 21
www.talkingcells.org
Effect of prostaglandin E2 on eicosanoid release by human
bronchial biopsy specimens from normal and inflamed mucosa.
1Schäfer D, 1Lindenthal U, 2Wagner M, 2Bolcskei PL, 1Baenkler HW.
Thorax. 1996 Sep;51(9):919-23.
1Dept. of Allergology, University of Erlangen-Nürnberg, Germany, 2Dept. of Pneumologie, University Hospital-Nürnberg.
BACKGROUND: Eicosanoids such as prostaglandin E2 (PGE2), thromboxane A2
(TXA2), and peptidoleukotrienes (pLT) are known to be biologically highly active
lipid mediators, especially in human lung epithelium. PGE2 is thought to have
mostly bronchoprotective effects, whereas pLT and TXA2 are bronchoconstrictive.
This study was undertaken to assess the release and interaction of eicosanoids in
human bronchial biopsy specimens of normal and inflamed mucosa.
METHODS: Bronchial biopsy specimens were obtained from 16 patients, seven
controls without signs of inflammation and nine patients with severe
inflammatory processes in the epithelium. The release of pLT, TXA2 (measured
as TXB2), and PGE2 was investigated using a "functional in vitro test" and the
addition of several stimuli.
RESULTS: Specimens incubated with arachidonic acid released higher amounts
of pLT, TXB2, and PGE2 than unstimulated specimens. Preincubation with PGE2
revealed significant inhibition of arachidonic acid-induced release of pLT and
TXB2 (> 50%). The inhibitory effect was higher in normal than in inflamed
epithelium.
CONCLUSIONS: Exogenous PGE2 has inhibitory effects on the release of pLT
and TXB2 in human bronchial biopsy specimens. This finding could explain the
bronchoprotective effect of inhaled PGE2 in normal subjects and asthmatic
subjects as direct eicosanoid interactions. It also supports the concept of PGE2 as
a bronchoprotective endogenous substance. The complex effects of PGE2 as a
modulating mediator in inflammation may be worth investigating.
EICOSANOIDE - ihre Beteiligung an physiologischen und pathophysiologischen Prozessen �
TC Info+Veröffentlichungen-06-2005.doc 22
www.talkingcells.org
Eicosanoide und Haut
Stimulated prostaglandin E2 release from rat skin, in vitro
1Sauer SK, 2Schafer D, 1Kress M, 1Reeh PW.
Life Sci. 1998; 62(22): 2045-255.
1Institut für Physiologie und Experimentelle Pathophysiologie, 2Medical Clinic III, Dept. of Allergology, Universität Erlangen-Nürnberg, Erlangen, Germany.
The excitatory effect of bradykinin (BK) and of low pH on nociceptors appears to
partly depend on secondary release of prostaglandins from the surrounding
tissue. Rat skin, in vitro, is introduced as a novel model to measure basal and
stimulated release of PGE2 and, in future, other substances relevant to
nociception, such as neuropeptides.
Flaps of hairy skin (n=57) from the rat saphenous region of the hindpaw were
subcutaneously excised and fixed on acrylic rods, the corium side exposed. The
preparations were equilibrated in carbogen gassed "synthetic interstitial fluid"
(SIF) for 30 minutes. The skin flaps were then immersed for 5 minutes each in 9
consecutive glass tubes, which were mounted in a shaking bath at 32 degrees C.
Each tube was filled with 5 ml of gassed SIF, the third tube contained
inflammatory mediator(s) dissolved in SIF or solutions of low pH. After passage
of the skin flap, the eluates were deep frozen (-70 degrees C) and the PGE2
content measured, off-line, using an enzyme immuno-assay.
As stimulants, BK at 10(-5) M (n=9) and 10(-6) M (n=4) and BK in equimolar
combination with histamine (HA) and serotonin (5-HT; 10(-5) M: n=8, 10(-6) M:
n=6, 10(-7) M: n=6) dose-dependently increased PGE2 release. Considering the
total amount of PGE2 secreted the combination of inflammatory mediators
caused a significantly greater release of PGE2 at 10(-5) and 10(-6) M (p<0.01,
Kruskal-Wallis test) than BK stimulation alone.
Racemic flurbiprofen caused a profound depression of basal and stimulated
release. Solutions of high proton concentration are known to stimulate and
sensitize nociceptors. However, phosphate buffered SIF at pH 6.1 and 6.4 caused
a substantial and significant decrease of the PGE2 release, probably due to low-
pH block of phospholipases. Thus, algogenic potency of mediators does not
necessarily match their pro-inflammatory action.
EICOSANOIDE - ihre Beteiligung an physiologischen und pathophysiologischen Prozessen �
TC Info+Veröffentlichungen-06-2005.doc 23
www.talkingcells.org
Eicosanoide Magen-Darm-Kanal
Abnormal eicosanoid pattern by blood leukocytes in
gastroduodenal ulcer.
Baenkler HW, Zeus J, Schenk J, Schäfer D.
Med Sci Monit. 2004 Oct;10(10):CR557-62. Epub 2004 Sep 23.
University Hospital, Department of Medicine III, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
BACKGROUND: Non-steroidal anti-inflammatory drugs (NSAIDs) are
implicated in several diseases showing altered tissue and leukocyte eicosanoid
patterns, such as nasal polyposis and asthma. NSAIDs are also associated with
gastrointestinal lesions, but it is unknown whether there is an altered eicosanoid
pattern.
MATERIAL/METHODS: The ex vivo modulated syntheses of prostaglandin E2
(PGE2) and peptido-leukotrienes (pLT) by leukocytes from 41 patients with
gastroduodenal ulcer were compared with those of 61 healthy controls. Samples
were incubated with diluent, arachidonic acid, or acetylsalicylic acid. The
individual syntheses of PGE2 and pLT were quantified using competitive enzyme-
immuno-assays followed by calculation of individual eicosanoid patterns.
RESULTS: Controls synthesized approximately 4.9-fold whereas patients only
approximately 2.9-fold more PGE2 than pLT due to higher basal synthesis of pLT
(67 and 125 pg/ml, respectively). The baseline PGE2/pLT ratio was slightly
higher in patients (6.1) than in controls (5.7). The arachidonic acid-induced
PGE2/pLT ratio in patients (14.2) was significantly higher than in controls (3.3).
The acetylsalicylic acid-induced PGE2/pLT ratio in patients (3.5) was significantly
lower than in controls (8.3) due to diminished PGE2 and elevated pLT. Integrated
individual PGE2 and pLT values revealed a highly significantly altered eicosanoid
pattern score in approximately 95% patients and approximately 12% controls.
CONCLUSIONS: There is strong evidence of an altered eicosanoid pattern
generated by leukocytes of gastroduodenal ulcer patients, which became obvious
upon in vitro modulation by arachidonic or acetylsalicylic acid. The phenomenon
of an abnormal eicosanoid pattern in gastroduodenal ulcer is yet not fully
understood, but may have implications in pathophysiology and diagnostics.
EICOSANOIDE - ihre Beteiligung an physiologischen und pathophysiologischen Prozessen �
TC Info+Veröffentlichungen-06-2005.doc 24
www.talkingcells.org
Eicosanoide und Nervensystem
Up-regulation of cyclooxygenase-1 in neuroblastoma cell lines by
retinoic acid and corticosteroids.
1Schneider N, 1Lanz S, 1Ramer R, 2Schaefer D, 1Goppelt-Struebe M.
J Neurochem. 2001 Apr;77(2):416-24.
1Medizinische Klinik IV, Universitat Erlangen-Nürnberg, Erlangen, Germany 2Kompetenzzentrum Umweltmedizin, Rupprecht-Karls-Universitat Heidelberg, Mannheim, Germany.
Cyclooxygenases-1 and -2 are both expressed in neuronal cells in vivo. In the
neuroblastoma cell lines NG108 and N2a, however, only cyclooxygenase-1 was
detectable. Differentiation of the cells with retinoic acid increased
cyclooxygenase-1 mRNA and protein expression within 24 and 48 h, respectively.
A further increase was observed when the cells were concomitantly treated with
the glucocorticoid dexamethasone (a 2-3-fold increase compared with retinoic
acid alone). In the absence of retinoic acid, dexamethasone only slightly up-
regulated cyclooxygenase-1 expression. The inhibitor of protein synthesis
cycloheximide abrogated the effect of dexamethasone, indicating the
involvement of newly synthesised proteins. Retinoic acid increased the
transcription of cyclooxygenase-1 mRNA, determined with a luciferase-coupled
promoter construct. Dexamethasone only slightly augmented cyclooxygenase-1-
promoter activity but increased cyclooxygenase-1 mRNA stability. Other
corticosteroids, hydrocortisone and aldosterone, also up-regulated
cyclooxygenase-1 whereas neurosteroids or oestrogen were ineffective. Up-
regulation was mediated primarily by the glucocorticoid receptor, because the
receptor antagonist RU486 strongly reduced the effects of all corticosteroids.
This indicated that in NG108 cells, the mineralocorticoid aldosterone may bind to
the glucocorticoid receptor. Treatment of NG108 or N2a cells with corticosteroids
did not alter the morphological phenotype obtained during differentiation.
We thus show that corticosteroids, which down-regulate cyclooxygenase
expression in most cell types, up-regulate cyclooxygenase-1 during neuronal
differentiation.
EICOSANOIDE - ihre Beteiligung an physiologischen und pathophysiologischen Prozessen �
TC Info+Veröffentlichungen-06-2005.doc 25
www.talkingcells.org
Thromboxane A2 release in ischemia and reperfusion of
free flaps in rats, studied by microdialysis.
Ionac M, Schaefer D, Geishauser M.
J Reconstr Microsurg. 2001 Feb;17(2):139-43.
Second Surgical Clinic, University of Medicine and Pharmacy, Timisoara, Romania.
Several studies have implicated enhanced eicosanoid production in reperfusion
injury. The reported study investigated the use of microdialysis in the in vivo
measurement of thromboxane levels during reperfusion in ischemic and
reperfused experimental free muscle flaps.
Microdialysis probes were inserted, via a guide, into the gracilis and
semitendinosus free flap in the rat. The probe was perfused at a flow of 5
microl/min, with samples collected at intervals of 20 min, and analyzed by the
ELISA technique. Animals were randomly distributed into three groups. After
ischemic periods of 2, 4, and 6 hr, respectively, the free muscle flaps were
revascularized on the contralateral femoral vessels.
The mean thromboxane level during ischemia was 1785.34 +/- 124.81 pg/ml.
The mean levels of thromboxane rose significantly (p < 0.05), compared to base
level, with 151.65 percent in the 2-hr ischemia group, 192.33 percent in the 4-hr
ischemia group, and 294.69 percent in the 6-hr ischemia group, and correlated
well with histologic observations.
The results suggest that a microdialysis technique, combined with a sensitive
assay for measuring thromboxane, is a useful method for in vivo monitoring of
inflammatory processes during ischemia and reperfusion. The evolution of
thromboxane release following 6 hr of ischemia indicates that this mediator may
be involved in facilitation of cell death, following ischemia and reperfusion, since
its tissue level correlates with histologic tissue damage.
EICOSANOIDE - ihre Beteiligung an physiologischen und pathophysiologischen Prozessen �
TC Info+Veröffentlichungen-06-2005.doc 26
www.talkingcells.org
Eicosanoide und Zahnheilkunde
Influence of resin-based restoration materials on cytotoxicity in
gingival fibroblasts.
Willershausen B, Schafer D, Pistorius A, Schulze R, Mann W.
Eur J Med Res. 1999 Apr 27; 4(4): 149-155.
Department of Restorative Dentistry and Periodontology, Augustusplatz 2, D-55131 Mainz, Germany.
Tooth-colored resin-based restoration materials have gained enormous significance in recent
decades. Since the composites presently available still evidence various weaknesses, intensive
research continues concerning them.
In this study we tested the biocompatibility of six resin-based materials (Charisma, Solitaire,
Definite, Tetric ceram, Ariston pHc and Compoglass) by means of cultured human gingival
fibroblasts. Over a period of 9 days the cured resin-based materials were incubated with the
fibroblasts. Cell growth, cell viability, and protein content was measured. The release of
prostaglandin (PGE2) was also determined.
There was a reduction of cell functions, related to the different resin-based materials. Protein
content of the fibroblasts was significantly reduced (Kruskal Wallis test; p = 0.0001),
depending on the material tested. Definite induced only minimal irritation, and there was
correspondingly little contrast to the protein content of the controls. Solitaire induced the
highest levels of irritation and the greatest reduction in protein content. Lactate production of
fibroblasts also showed some significant reduction in contact with particular materials (p =
0.005). There were only small differences among the tested materials as concerns measured
PGE2 release of the fibroblasts.
The data suggest that the methods here employed may be quite useful in testing the cytotoxic
potential of newly developed resin-based materials.
EICOSANOIDE - ihre Beteiligung an physiologischen und pathophysiologischen Prozessen �
TC Info+Veröffentlichungen-06-2005.doc 27
www.talkingcells.org
Cytotoxicity of root canal filling materials to three different human cell lines. Willershausen B, Marroquin BB, Schafer D, Schulze R. J Endod. 2000 Dec;26(12):703-7.
Department of Operative Dentistry and Periodontology, Johannes Gutenberg-University, Mainz,
Germany.
The aim of this study was to investigate the biological compatibility of five root canal sealers
(Sealapex, Endion, Super-EBA, Ketac-Endo, and AH Plus) and regular and calcium
hydroxide-based gutta-percha in three different human cell lines.
Cultures without root canal sealers were used as controls. Cell growth, cell morphology, cell
viability, protein content of the cells, and prostaglandin E2 (PGE2) release were used as
parameters to determine the cytotoxicity of the materials.
The protein content of the three cell lines--nasal fibroblasts, gingival fibroblasts, and
epithelial tumor cells was significantly reduced (p < or = 0.001) by all materials tested.
Determinations of PGE2 release showed significant material specific differences. No
significant increased PGE2 release values were found with Sealapex, Endion, and Super-
EBA.
On the contrary significantly increased PGE2 levels were measured with Ketac Endo, AH Plus, regular and calcium hydroxide-based gutta-percha points (p < or = 0.001).
EICOSANOIDE - ihre Beteiligung an physiologischen und pathophysiologischen Prozessen �
TC Info+Veröffentlichungen-06-2005.doc 28
www.talkingcells.org
Untersuchungen zur Zytotoxizität von Wurzelkanfüllmaterialien. 1Willershausen B, 1Briseno B, 2Schulze R 3Schäfer D,. Dtsch Zahnärztl Z 2000 ;55:252-256. 1 Poliklinik für Zahnerhaltungskunde, Johannes Gutenberg-University, Mainz, Germany. 2 Poliklinik für zahnärztliche Chirurgie, Johannes Gutenberg-University, Mainz, Germany, 3 Klinik für Hals-Nasen-Ohrenheilkunde, Gutenberg-University, Mainz, Germany
Die biologische Verträglichkeit von 4 Wurzelkanalzementen (Sealapex, Super EBA, Ketac-
Endo, AH Plus; Aushärtungsueit 24 Std.) sowie Guttaperchespitzen mit Claciumhydroxid wurde in drei verschiedenen Zellsystemen (Gingivafibroblasten, nasalen Epithelzellen und
epithelialen Tumorzellen) menschlichen Ursprungs über einen Zeitraum von 6 Tagen überprüft. Als Vergleich dienten Goldlegierungsproben und Zellen ohne Werkstoffe. Beobachtungsparameter waren Zellwachstum, Zellmorphologie, Zellvitalität (Fluoreszenztmarkierung), Proteingehalt der Zellen, und Freisetzung von Prostaglandin E2
(PGE2, clone E3R1).
Die getesteten Wurzelkanfüllungsmaterialien führten in den jeweils getesteten Zellsystemen zu materialabhängigen signifikanten Veränderungen der Zellfunktionen. Die Proteinsynthese war bei allen Materialien sowohl bei den nasalen und gingivalen Fibroblasten als auch bei den
epithelialen Tumorzellen signifikant vermindert (t-test, p<0,001). Die Bestimmung der PGE2-
Werte zeigte, dass gingivale und nasale Fibroblasten gleichfalls signifikante,
werkstoffabhängige veränderungen erkenn ließen, epitheliale Tumorzellen reagierten weniger sensibel. Keine Irritationen fanden sich für Sealpex und Super EBA, während Ketac Endo und
Ah Plus vermehrte Prostaglandinwerte bewirkten.
Die vorliegenden Untersuchungen unterstreichen, dass Fibroblastenkulturen ein geeignetes
Modellsystem darstellen, um die biologische Verträglichkeit von Wurzelkanalfüllmaterialien zu überprüfen.
EICOSANOIDE - ihre Beteiligung an physiologischen und pathophysiologischen Prozessen �
TC Info+Veröffentlichungen-06-2005.doc 29
www.talkingcells.org
Eicosanoide und Tumortherapie
The cyclooxygenase system participates in functional mdr1b
overexpression in primary rat hepatocyte cultures.
1Ziemann C, 2Schafer D, 1Rudell G, 1Kahl GF, 1Hirsch-Ernst KI.
Hepatology. 2002 Mar; 35(3): 579-588.
1Department of Toxicology, Institute of Pharmacology and Toxicology, University of Göttingen, Robert-Koch-Strasse 40, D-37075 Gottingen, 2Kompetenzzentrum Umweltmedizin, Rupprecht-Karls-Universitat Heidelberg, Mannheim, Germany.
Overexpression of mdr1-type P-glycoproteins (P-gps) is thought to contribute to primary chemotherapy resistance of untreated hepatocellular carcinoma. However, mechanisms of endogenous multidrug resistance 1 (mdr1) gene activation still remain unclear. Because recent studies have demonstrated overexpression of cyclooxygenase-2 (COX-2) in hepatocytes during early stages of hepatocarcinogenesis, we investigated whether the COX system, which catalyzes the rate-limiting step in prostaglandin synthesis, participates in mdr1 gene regulation. In the present study, primary rat hepatocyte cultures, exhibiting time-dependent mdr1b overexpression, demonstrated basal COX-2 and COX-1 mRNA expression and liberation of prostaglandin E(2) (PGE(2)), indicative of an active COX-dependent arachidonic acid metabolism. PGE(2) accumulation in culture supernatants was further enhanced by arachidonic acid (1mumol/L) and epidermal growth factor (EGF) (16 nmol/L). PGE(2) and prostaglandin F(2alpha) (PGF(2)alpha) (3-6mug/mL), added directly to the culture medium, significantly up-regulated intrinsic mdr1b mRNA overexpression and mdr1-dependent transport activity. Up-regulation was maximal after 3 days of culture. Like prostaglandins, the COX substrate, arachidonic acid, also induced mdr1b gene expression. Apart from this, structurally different COX inhibitors (indomethacin, meloxicam, NS-398) mediated significant inhibition of time-dependent and EGF-induced mdr1b mRNA overexpression, resulting in enhanced intracellular accumulation of the mdr1 substrate, rhodamine 123 (Rho123). Thus, the present data support the conclusion that the release of prostaglandins through activation of the COX system participates in endogenous mdr1b gene regulation. COX-2 inhibition might constitute a new strategy to counteract primary mdr1-dependent chemotherapy resistance.
EICOSANOIDE - ihre Beteiligung an physiologischen und pathophysiologischen Prozessen �
TC Info+Veröffentlichungen-06-2005.doc 30
www.talkingcells.org
Impact of the cyclooxygenase system on doxorubicin-induced
functional multidrug resistance 1 overexpression and doxorubicin
sensitivity in acute myeloid leukemic HL-60 cells.
1Puhlmann U, 2Ziemann C, 1Ruedell G, 1Vorwerk H, 3Schaefer D, 1Langebrake C, 1Schuermann P, 1Creutzig U, 1Reinhardt D.
J Pharmacol Exp Ther. 2005 Jan;312(1):346-54. Epub 2004 Oct 22.
1AML-BFM Study, Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster, Albert-Schweitzer-Str. 33, 48129 Münster, 21Department of Toxicology, Institute of Pharmacology and Toxicology, University of Göttingen, Robert-Koch-Strasse 40, D-37075 Göttingen, 3Kompetenzzentrum Umweltmedizin, Rupprecht-Karls-Universitat Heidelberg, Mannheim, Germany.
Multidrug resistance (MDR), a challenge in treating childhood acute myeloid leukemia (AML), is frequently associated with decreased drug accumulation caused by multidrug transporter MDR1. Doxorubicin, an important anti-AML drug, is a known MDR1 substrate and inducer. Its cytostatic efficacy is thus limited by MDR1 overexpression. A recent study demonstrated cyclooxygenase-2-dependent, prostaglandin E(2) (PGE(2))-mediated regulation of mdr1b expression in primary rat hepatocyte cultures. Cyclooxygenase-2 expression is increased in several malignancies and considered a negative prognostic factor. Our study focused on cyclooxygenase system's impact on drug-induced MDR1 overexpression in AML cells. As a prerequisite, coexpression of MDR1 and cyclooxygenase-2 mRNA in HL-60 cells and primary AML blasts was demonstrated by Northern blot. Interestingly, incubation of AML cells with doxorubicin not only induced functionally active MDR1 overexpression but also mediated increased cyclooxygenase-2 mRNA and protein expressions with subsequent PGE(2) release (determined by flow cytometry, rhodamine123 efflux assay, reverse transcription-polymerase chain reaction, and enzyme-linked immunosorbent assay). After preincubation and subsequent parallel treatment with the cyclooxygenase-2-preferential inhibitor meloxicam, doxorubicin-induced MDR1 overexpression and function were reduced (maximally at 0.1-0.5 microM meloxicam), whereas cytostatic efficacy of doxorubicin in 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide assays was significantly increased by up to 78 (HL-60) and 30% (AML blasts) after 72 h of doxorubicin treatment. In HL-60 cells, meloxicam-dependent effect on doxorubicin cytotoxicity was neutralized by PGE(2) preincubation. In conclusion, the cyclooxygenase system, especially the cyclooxygenase-2 isoform, might be involved in regulating doxorubicin-induced MDR1 overexpression in AML cells, with PGE(2) seeming to be a mediating factor. Cyclooxygenase inhibitors thus bear promise to overcome MDR in AML and improve therapy.
EICOSANOIDE - ihre Beteiligung an physiologischen und pathophysiologischen Prozessen �
TC Info+Veröffentlichungen-06-2005.doc 31
www.talkingcells.org
Eicosanoide und Regulation ihrer Synthese
Differential regulation of cyclo-oxygenase-2 and 5-lipoxygenase-
activating protein (FLAP) expression by glucocorticoids in
monocytic cells.
1Goppelt-Struebe M, 2Schaefer D, 1Habenicht AJ.
Br J Pharmacol. 1997 Oct;122(4):619-24.
1Department of Internal Medicine IV, University of Erlangen-Nürnberg, Erlangen, 2Medical Clinic III, Dept. of Allergology, Universität Erlangen-Nürnberg, Erlangen, Germany Germany.
1. The objective of the present study was to determine the effects of dexamethasone on key constituents of prostaglandin and leukotriene biosynthesis, cyclo-oxygenase-2 (COX-2) and 5-lipoxygenase activating protein (FLAP). The human monocytic cell line THP-1 was used as a model system. mRNA and protein levels of COX-2 and FLAP were determined by Northern and Western blot analyses, respectively. 2. Low levels of COX-2 and FLAP mRNA were expressed in undifferentiated THP-1 cells, but were induced upon differentiation of the cells along the monocytic pathway by treatment with phorbol ester (TPA, 5 nM). Maximal expression was observed after two days. 3. Coincubation of the undifferentiated cells with dexamethasone (10(-9) - 10(-6) M) and phorbol ester prevented induction of COX-2 mRNA, but did not affect the induction of FLAP mRNA. 4. Dexamethasone downregulated COX-2 mRNA and protein in differentiated, monocyte-like THP-1 cells. In contrast, FLAP mRNA and protein were upregulated by dexamethasone in differentiated THP-1 cells. After 24 h, FLAP mRNA levels were increased more than 2 fold. Dexamethasone did not change 5-lipoxygenase mRNA expression. 5. Release of prostaglandin E2 (PGE2) and peptidoleukotrienes was determined in cell culture supernatants of differentiated THP-1 cells by ELISA. Calcium ionophore-dependent PGE2 synthesis was associated with COX-2 expression, whereas COX-1 and COX-2 seemed to participate in arachidonic acid-dependent PGE2 synthesis. Very low levels of peptidoleukotrienes were released from differentiated THP-1 cells upon incubation with ionophore. Treatment with dexamethasone did not significantly affect leukotriene release. 6. These data provide evidence that prostaglandin synthesis is consistently downregulated by glucocorticoids. However, the glucocorticoid-mediated induction of FLAP may provide a mechanism to maintain leukotriene biosynthesis through more efficient transfer of arachidonic acid to the 5-lipoxygenase reaction, in spite of inhibitory effects on other enzymes of the biosynthetic pathway.
EICOSANOIDE - ihre Beteiligung an physiologischen und pathophysiologischen Prozessen �
TC Info+Veröffentlichungen-06-2005.doc 32
www.talkingcells.org
ABSRTACTS - KURZÜBERSICHT Eicosanoide und Atemwege
1. Hosemann WG, Baenkler HW, Gunther F. ASA-induced release of histamine from nasal mucous membranes in analgesic intolerance and polyposis nasi. Rhinology 1990 Dec; 28(4): 231-238.
2. Baenkler HW, Schäfer D, Hosemann W. Eicoanoid pattern in nasal polyps and nasal mucosa. Rhinology 1996; 34: 166-170.
3. SchäferD, Lindenthal U, Wagner M, Bölcskei PL, Baenkler HW. Effect of prostaglandin E2 on eicosanoid release by human bronchial biopsy specimens from normal and inflamed mucosa. Thorax 1996; 51: 919-932.
4. Schäfer D, Schmid M, Göde U, Baenkler HW. Dynamics of eicosanoids in peripheral blood cells during bronchial provication in aspirin-intolerant asthmatics. Eur Respir J, 1999; 13: 638-646.
5. Schmid M, Göde U, Schäfer D, Wiegand ME. Arachidonic acid metabolism in nasal tissue and peripheral blood cells in aspirin intolerant asthmatics. Act Otholaryngol (Stockh) 1999; 199: 277-280.
6. Kaldenbach T, Schäfer D, Gosepath J, Bittinger F, Klimek L, Mann WJ. Die Bedeutung eosinophiler Granulocyten in Beziehung zu Allergie und Aspirin-Intoleranz bei Patienten mit Sinusitis polyposa. Laryngo Rhino Otol 1999; 78: 429-434.
7. Gosepath J, Hoffmann F, Schäfer D, Amedee RG, Mann WJ. Aspirin Intolerance in patients with chronic sinusitis. ORL 1999; 61: 146-150.
8. Mohammadian P, Schaefer D, Hummel T, Kobal G. Experimental induced nasal irritation. Rhinology 1999; 37: 176-178.
9. Gosepath J, Schäfer D, Amedee RG, Mann WJ. Individual monitoring of aspirin desensitization. Arch Otolaryngol Head Neck Surg 2001; 127: 316-321.
10. Grundmann T., Töpfer M.. Leukotrienrezeptorantagonisten zur Rezidivprophylaxe bei der ASS-assoziierten Polyposis - Erste klinische Ergebnisse zur Wirkung auf entzündliche
EICOSANOIDE - ihre Beteiligung an physiologischen und pathophysiologischen Prozessen �
TC Info+Veröffentlichungen-06-2005.doc 33
www.talkingcells.org
Gewebeprozesse. Laryngorhinootologie 2001; 80: 576-582.
11. Gosepath J, Schäfer D, Mann WJ. Analgetika-Intoleranz: Langzeitergebnisse bis zu 3 Jahren be adaptativer Desaktivierung mit einer täglichen Erhaltungsdosis von 100 mg Aspirin. Laryngo-Rhino-Otol 2002; 81: 732-738.
12. Haxel BR, Schäfer D, Klimek L, Mann WJ. Prostaglandin E2 activates the ciliary beat frequency of cultured human nasal mucosa via second messanger cyclic adenosine monophosphate. Eur Arch Otorhinolaryngol 2001; 258: 230-235.
13. Hecksteden K, Schäfer D, Stuck BA, Klimek L, Hörmann K. Diagnosk des Analgetika-Intoleranz-Syndroms mittels funktioneller Zelltestung (analgetika-Intoleranz-Test: AIT). Allergologie 2003; 26: 263-271.
14. Kuehnemund M, Ismail C, Brieger J, Schaefer d, Mann WJ. Untreated chronic Rhinosinusitis: a comparison of symptoms and mediator profiles. The Laryngoscope, 2004;114:561-565.
15. Eger G, D Schäfer, HW Baenkler. Analgetikasensitive Atemwegserkrankung: Diagnostik, Risikoanalyse und Therapieplanung mittels FET Pneumologie 2004; 58
Eicosanoide und Haut 1. Sauer SK, Schafer D, Kress M, Reeh PW.
Stimulated prostaglandin E2 release from rat skin, in vitro Life Sci. 1998; 62(22): 2045-255.
Eicosanoide und Magen-Darm-Kanal 1. Baenkler HW, Zeus J, Schenk J, Schäfer D.
Abnormal eicosanoid pattern by blood leukocytes in gastroduodenal ulcer. Med Sci Monit. 2004 Oct;10(10):CR557-62. Epub 2004 Sep 23.
Eicosanoide und Nervensystem 1. Schneider N, Lanz S, Ramer R, Schaefer D, Goppelt-Struebe M.
Up-regulation of cyclooxygenase-1 in neuroblastoma cell lines by retinoic acid and corticosteroids. J Neurochem. 2001 Apr;77(2):416-24.
EICOSANOIDE - ihre Beteiligung an physiologischen und pathophysiologischen Prozessen �
TC Info+Veröffentlichungen-06-2005.doc 34
www.talkingcells.org
2. Ionac M, Schaefer D, Geishauser M. Thromboxane A2 release in ischemia and reperfusion of free flaps in rats, studied by microdialysis. J Reconstr Microsurg. 2001 Feb;17(2):139-43.
Eicosanoide und Zahnheilkunde 1. Willershausen B, Schafer D, Pistorius A, Schulze R, Mann W.
Influence of resin-based restoration materials on cytotoxicity in gingival fibroblasts Eur J Med Res. 1999 Apr 27; 4(4): 149-155.
2. Willershausen B, Marroquin BB, Schafer D, Schulze R. Cytotoxicity of root canal filling materials to three different human cell lines. J Endod. 2000 Dec;26(12):703-7.
3. Willershausen B, Briseno b, Schulz R, Schäfer D. Untersuchungen zur Zytotoxicität von Wurzelkanalfüllmaterialien. Dtsch Zahnärztl Z 2000;55:252-256.
Eicosanoide und Tumortherapie 1. Ziemann C, Schafer D, Rudell G, Kahl GF, Hirsch-Ernst KI.
The cyclooxygenase system participates in functional mdr1b overexpression in primary rat hepatocyte cultures Hepatology. 2002 Mar; 35(3): 579-588
2. Puhlmann U, Ziemann C, Ruedell G, Vorwerk H, Schaefer D, Langebrake C, Schuermann P, Creutzig U, Reinhardt D Impact of the cyclooxygenase system on doxorubicin-induced functional multidrug resistance 1 overexpression and doxorubicin sensitivity in acute myeloid leukemic HL-60 cells. J Pharmacol Exp Ther. 2005 Jan;312(1):346-54. Epub 2004 Oct 22.
Eicosanoide und Regulation ihrer Synthese 1. Goppelt-Struebe M, Schaefer D, Habenicht AJ..
Differential regulation of cyclo-oxygenase-2 and 5-lipoxygenase-activating protein (FLAP) expression by glucocorticoids in monocytic cells. Br J Pharmacol. 1997 Oct;122(4):619-24.
Recommended